These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 37029389)

  • 1. Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines.
    Guo X; Liu D; Huang Y; Deng Y; Wang Y; Mao J; Zhou Y; Xiong Y; Gao X
    Virol J; 2023 Apr; 20(1):64. PubMed ID: 37029389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?
    Sehrawat S; Osterrieder N; Schmid DS; Rouse BT
    Microbes Infect; 2023; 25(1-2):105078. PubMed ID: 36435367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.
    Trougakos IP; Terpos E; Alexopoulos H; Politou M; Paraskevis D; Scorilas A; Kastritis E; Andreakos E; Dimopoulos MA
    Trends Mol Med; 2022 Jul; 28(7):542-554. PubMed ID: 35537987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in mRNA vaccines for viral diseases.
    Huang Y; Zhu X; Guo X; Zhou Y; Liu D; Mao J; Xiong Y; Deng Y; Gao X
    J Med Virol; 2023 Jul; 95(7):e28924. PubMed ID: 37417396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
    Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Development of mRNA Vaccines: Challenges and Opportunities.
    August A; Brito L; Paris R; Zaks T
    Curr Top Microbiol Immunol; 2022; 440():167-186. PubMed ID: 35906319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in mRNA vaccines.
    Li M; Wang Z; Xie C; Xia X
    Int Rev Cell Mol Biol; 2022; 372():295-316. PubMed ID: 36064266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
    Chaudhary N; Weissman D; Whitehead KA
    Nat Rev Drug Discov; 2021 Nov; 20(11):817-838. PubMed ID: 34433919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA vaccines: a transformative technology with applications beyond COVID-19.
    Overmars I; Au-Yeung G; Nolan TM; Steer AC
    Med J Aust; 2022 Jul; 217(2):71-75. PubMed ID: 35780474
    [No Abstract]   [Full Text] [Related]  

  • 16. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
    Teo SP
    J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases.
    Yang L; Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():896958. PubMed ID: 35928814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.
    Rouf NZ; Biswas S; Tarannum N; Oishee LM; Muna MM
    RNA Biol; 2022; 19(1):386-410. PubMed ID: 35354425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.
    Mirtaleb MS; Falak R; Heshmatnia J; Bakhshandeh B; Taheri RA; Soleimanjahi H; Zolfaghari Emameh R
    Int Immunopharmacol; 2023 Apr; 117():109934. PubMed ID: 36867924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.